MedTrace Logo

Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies

NCT05850871 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 427

Last updated 2023-05-09

No results posted yet for this study

Summary

The first aim of this study is to explore the drug resistance mechanism of Enterobacteriaceae bacteria and to evaluate the treatment effect of ceftazidime-avibactam (CAZ-AVI) in combination with aztreonam (ATM) against Metallo-β-lactamases (MBL) producing Enterobacterales in vivo. The investigators then use CRISPR/Cas9 technology to remove Enterobacteriaceae bacteria resistance and virulence genes

Conditions

  • Carbapenem-Resistant Enterobacteriaceae Infection

Interventions

DRUG

CAZ/AVI plus Aztreonam

Samples of the patients will be examined such as the routine blood test, blood culture et al.

OTHER

Conventional treatment

Conventional treatment

Sponsors & Collaborators

  • Qianfoshan Hospital

    lead OTHER

Principal Investigators

  • Jiasheng Zhang, Doctor · Shandong First Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-06
Primary Completion
2025-01-31
Completion
2025-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05850871 on ClinicalTrials.gov